Evaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Brooks, James D ^a   Wei, Wei ^b   Hawley, Sarah ^a   Auman, Heidi ^a   Newcomb, Lisa ^c   Boyer, Hilary ^d   Fazli, Ladan ^d   Simko, Jeff ^e   Hurtado Coll, Antonio ^f   Troyer, Dean A ^f,g   Carroll, Peter R ^h   Gleave, Martin ^d   Lance, Raymond ^g   Lin, Daniel W ^c   Nelson, Peter S ⁱ   Thompson, Ian M ^f   True, Lawrence D ^c   Feng, Ziding ^b   McKenney, Jesse K ^j  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f University of Texas Health Science Center   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN SPINK1; SERINE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; CARRIER PROTEIN; ERG PROTEIN, HUMAN; SPINK1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; DISEASE SPECIFIC SURVIVAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; TISSUE MICROARRAY; VERY ELDERLY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; STAINING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARRIER PROTEINS; COHORT STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; STAINING AND LABELING; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG; TREATMENT OUTCOME;

EID: 84940751168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132343     Document Type: Article

References (49)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015; 65(1):5-29. doi: 10.3322/caac.21254 PMID: 25559415.
2. Brooks JD. Managing localized prostate cancer in the era of prostate-specific antigen screening. Cancer. 2013; 119(22):3906-9. doi: 10.1002/cncr.28301 PMID: 24006273; PubMed Central PMCID: PMC3875624.
3. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. Epub 2009/03/20.NEJMoa0810696 [pii] doi: 10.1056/NEJMoa0810696 PMID: 19297565.
4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367(3):203-13. Epub 2012/07/20. doi: 10.1056/NEJMoa1113162 PMID: 22808955; PubMed Central PMCID: PMC3429335.
5. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370(10):932-42. doi: 10.1056/NEJMoa1311593 PMID: 24597866; PubMed Central PMCID: PMC4118145.
6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-90. Epub 2012/03/16. doi: 10.1056/NEJMoa1113135 PMID: 22417251.
7. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358(12):1250-61. Epub 2008/03/21. 358/12/1250 [pii] doi: 10.1056/NEJMoa074311 PMID: 18354103.
8. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014; 66(3):550-60. doi: 10.1016/j.eururo.2014.05.004 PMID: 24836057.
9. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994; 8(3):439-43. Epub 1994/05/01. PMID: 7803731.
10. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, et al. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013; 20(1):39-44. doi: 10.1097/PAP.0b013e31827b665b PMID: 23232570; PubMed Central PMCID: PMC3535290.
11. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. doi: 10.1126/science.1117679 PMID: 16254181.
12. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer cell. 2008; 13(6):519-28. doi: 10.1016/j.ccr.2008.04.016 PMID: 18538735; PubMed Central PMCID: PMC2732022.
13. Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, et al. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. Hum Pathol. 2014; 45(3):488-97. doi: 10.1016/j.humpath.2013.10.012 PMID: 24406017.
14. Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014; 20(18):4904-11. doi: 10.1158/1078-0432.CCR-13-1341 PMID: 24687926; PubMed Central PMCID: PMC4167171.
15. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011; 35(7):1014-20. doi: 10.1097/PAS.0b013e31821e8761 PMID: 21677539; PubMed Central PMCID: PMC3505676.
16. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7):590-8. PMID: 20651988; PubMed Central PMCID: PMC2907585.
17. Leinonen KA, Saramaki OR, Furusato B, Kimura T, Takahashi H, Egawa S, et al. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol, Biomarkers & Prev. 2013; 22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T PMID: 24083995; PubMed Central PMCID: PMC4086660.
18. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26(31):4596-9. doi: 10.1038/sj.onc.1210237 PMID: 17237811.
19. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res. 2010; 16(10):2845-51. doi: 10.1158/1078-0432.CCR-09-2505 PMID: 20442300.
20. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013; 19(9):2442-50. doi: 10.1158/1078-0432.CCR-12-3283 PMID: 23515404; PubMed Central PMCID: PMC3674574.
21. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, et al. Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. Urology. 2009. Epub 2009/08/04. S0090-4295(09)00387-2 [pii] doi: 10.1016/j.urology.2009.01.087 PMID: 19647299.
22. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15(14):4706-11. Epub 2009/07/09. 1078-0432.CCR-08-2927 [pii] doi: 10.1158/1078-0432.CCR-08-2927 PMID: 19584163
23. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Brit J Cancer. 2010; 102(4):678-84. doi: 10.1038/sj.bjc.6605554 PMID: 20104229; PubMed Central PMCID: PMC2837564.
24. Weinmann S, Van Den Eeden SK, Haque R, Chen C, Richert-Boe K, Schwartzman J, et al. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. Prostate. 2013; 73(13):1371-7. doi: 10.1002/pros.22684 PMID: 23661613; PubMed Central PMCID: PMC3745520.
25. Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res. 2009; 15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176 PMID: 19825963.
26. Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG, et al. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol. 2014; 66(5):851-60. doi: 10.1016/j.eururo.2014.02.058 PMID: 24630684.
27. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol, Biomarkers & Prev. 2012; 21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042 PMID: 22736790; PubMed Central PMCID: PMC3671609.
28. Schaefer G, Mosquera JM, Ramoner R, Park K, Romanel A, Steiner E, et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 2013; 16(2):132-8. doi: 10.1038/pcan.2013.4 PMID: 23381693; PubMed Central PMCID: PMC3655380.
29. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013; 153(3):666-77. doi: 10.1016/j.cell.2013.03.021 PMID: 23622249; PubMed Central PMCID: PMC3690918.
30. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-43. doi: 10.1038/nature11125 PMID: 22722839; PubMed Central PMCID: PMC3396711.
31. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Modern Pathol. 2009; 22(7):866-71. doi: 10.1038/modpathol.2009.57 PMID: 19396154.
32. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011; 71(5):489-97. doi: 10.1002/pros.21265 PMID: 20878952.
33. King CR, Ferrari M, Brooks JD. Prognostic significance of prostate cancer originating from the transition zone. Urologic Oncol. 2009; 27(6):592-7. doi: 10.1016/j.urolonc.2008.05.009 PMID: 18799332.
34. Lee JJ, Thomas IC, Nolley R, Ferrari M, Brooks JD, Leppert JT. Biologic differences between peripheral and transition zone prostate cancer. Prostate. 2015; 75(2):183-90. doi: 10.1002/pros.22903 PMID: 25327466; PubMed Central PMCID: PMC4270836.
35. Lichtensztajn DY, Gomez SL, Sieh W, Chung BI, Cheng I, Brooks JD. Prostate cancer risk profiles of Asian-American men: disentangling the effects of immigration status and race/ethnicity. J Urol. 2014; 191(4):952-6. doi: 10.1016/j.juro.2013.10.075 PMID: 24513166; PubMed Central PMCID: PMC4051432.
36. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011; 17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251 PMID: 21791629.
37. Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, et al. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate. 2013; 73(15):1690-8. doi: 10.1002/pros.22707 PMID: 23843146.
38. Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maille P, et al. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer. 2015. doi: 10.1002/cncr.29233 PMID: 25639219.
39. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU international. 2009; 103(9):1256-69. doi: 10.1111/j.1464-410X.2008.08200.x PMID: 19040532.
40. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature genetics. 2009; 41(5):619-24. doi: 10.1038/ng.370 PMID: 19396168; PubMed Central PMCID: PMC2835150.
41. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Modern Pathol. 2012; 25(11):1543-9. doi: 10.1038/modpathol.2012.104 PMID: 22684219.
42. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. The Am J Pathol. 2012; 181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026 PMID: 22705054.
43. Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. J Hematol& Oncology. 2014; 7:21. doi: 10.1186/1756-8722-7-21 PMID: 24606912; PubMed Central PMCID: PMC3975646.
44. Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, et al. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. Genes, chromosomes & cancer. 2012; 51(8):781-91. doi: 10.1002/gcc.21963 PMID: 22505341.
45. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, et al. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010; 70(22):8994-9002. doi: 10.1158/0008-5472.CAN-10-1358 PMID: 21062978.
46. Sirma H, Broemel M, Stumm L, Tsourlakis T, Steurer S, Tennstedt P, et al. Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncology Letters. 2013; 6(5):1245-52. doi: 10.3892/ol.2013.1563 PMID: 24179503; PubMed Central PMCID: PMC3813765.
47. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, et al. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. Eur Urol. 2015. doi: 10.1016/j.eururo.2015.04.033 PMID: 25964175.
48. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, et al. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res. 2015; 21(7):1621-7. doi: 10.1158/1078-0432.CCR-14-1961 PMID: 25593303.
49. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, et al. Therapeutic targeting of SPINK1-positive prostate cancer. Science Translational Med. 2011; 3(72):72ra17. doi: 10.1126/scitranslmed.3001498 PMID: 21368222; PubMed Central PMCID: PMC3211047.